Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ACMZ | ISIN: US4622221004 | Ticker-Symbol: ISI
Tradegate
28.03.24
15:41 Uhr
41,030 Euro
+0,840
+2,09 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
IONIS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
IONIS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
39,70040,68028.03.
40,00040,37028.03.

Aktuelle News zur IONIS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoIonis reports positive results for rare disease treatment8
MoCan Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?5
14.03.Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals7
13.03.Ionis maintains buy rating, $68 stock target from Laidlaw6
13.03.Ionis reports promising Phase 2 results for MASH treatment3
13.03.With first MASH drug due for FDA nod, Ionis says me too with phase 2 data4
13.03.Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows3
13.03.Ionis Pharma rises as liver disease drug meets main goal in mid-stage trial3
13.03.Ionis stock jumps as MASH drug succeeds in mid-stage trial4
13.03.Ionis Pharmaceuticals, Inc.: Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH65Significant improvement in steatohepatitis with >2 point improvement in NAS score without worsening fibrosis, the primary endpoint of the study Achieved key secondary endpoint of MASH resolution without...
► Artikel lesen
13.03.Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial4
29.02.Kyle Jenne Rejoins Ionis Pharmaceuticals as EVP, Chief Global Product Strategy Officer4
29.02.Kyle Jenne returns to Ionis Pharmaceuticals as Executive VP3
29.02.IONIS PHARMACEUTICALS INC - 8-K, Current Report1
22.02.Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y13
22.02.Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals8
21.02.IONIS PHARMACEUTICALS INC - 10-K, Annual Report2
21.02.IONIS PHARMACEUTICALS INC - 8-K, Current Report2
21.02.Ionis Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary8
21.02.Ionis Pharmaceuticals rises on Q4 revenue beat3
Seite:  Weiter >>
82 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1